About us

Developing a new class of drugs for millions of patients suffering from cardio-renal pathologies with no therapeutic solution

V4Cure is based on CEA research into the use of animal toxins as a source of therapeutic molecules. The start-up is focusing its efforts on one of them, V4C-232, with two indications in cardio-renal diseases.

V4C-232 is a first in class molecule. It is derived from a molecule found in the venom of the green mamba, a sub-Saharan African snake. Potency and safety of V4C-232 molecule to treat hyponatremia and polycystic kidney disease, was demonstrated in preclinical studies.

V4Cure is primarily developing the indication of hyponatremia in hospitalized patients. Hyponatremia is an abnormal low level of sodium in the blood. The neurological symptoms of this condition go from mild to severe, such as headache, dizziness to seizures, coma. V4C-232 will represent a safe and effective solution to control natremia

V4Cure is conducting pharmacological studies and drug candidate developments, to then launch phase 1 and 2 clinical studies. In the meantime, it is developing another V4C-232 based product as a new therapy for polycystic kidney diseases. These rare chronic genetic progressive diseases lead to renal failure disorders, for which therapeutic options are limited.


Prevalence of ARPKD is estimated to be annualized prevalence is 1.17 per 100,000 (1 in 20:000 births)

Our Team

A seasoned team of healthcare professionals with complementary expertise

Dr. Sonia Escaich


PhD in Human biology
25-years in Pharma R&D, 20 years biotechs management & creation

Dr. Thierry Verrecchia


PharmD, PhD in immunochemistry
20 years in pharma industry
10 years on the equity market

Dr. Nicolas Gilles

Scientific advisor

PhD in biochemical pharmacology
20-years in Research at CEA
5 patents and 76 publications

Henry Dorbes


MBA, International Finance expertise in large and small companies in Healthcare

Nabil Gharios

Board member

Centrale Engineer, Former Abbott executive, 20-years experience in M&A, financial investment Life Science






V4Cure is a spin off from CEA

V4Cure received in 2022 the national ILAB grant
for innovation with the Honor Award.

V4Cure is a member of Paris Biotech Santé Biotech incubator.


Coming soon.


Contact us